Cost-effectiveness of Oral Phenytoin, Intravenous Phenytoin, and Intravenous Fosphenytoin in the Emergency Department

Annals of Emergency Medicine

Volumn 43, Issue 3, 2004, Pages 386-397

  Rudis, Maria I ^a,b   Touchette, Daniel R ^c   Swadron, Stuart P ^b   Chiu, Amy P ^a,d   Orlinsky, Michael ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d John Muir Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSPHENYTOIN SODIUM; PHENYTOIN;

ARTICLE; ATAXIA; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISORIENTATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; EMERGENCY TREATMENT; EMERGENCY WARD; HEALTH CARE PERSONNEL; HEART ARRHYTHMIA; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; MANPOWER; MEDICAL DECISION MAKING; NAUSEA; NYSTAGMUS; PAIN; PHLEBITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SAFETY; SEIZURE; TACHYCARDIA; TIME; VOMITING;

EID: 1442287104     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2003.10.011     Document Type: Article

References (27)

1. Krumholz A, Grufferman S, Orr ST, et al. Seizures and seizure care in an emergency department. Epilepsia. 1989;30:175-181.
2. Brokaw J, Olson L, Fullerton L, et al. Repeated ambulance use by patients with acute alcohol intoxication, seizure disorder, and respiratory illness. Am J Emerg Med. 1998;16:141-144.
3. Simonson HC, Pelberg AL. Unnecessary emergency transport and care of grand mal seizures. Am J Med Qual. 1993;8:53-55.
4. Osborn HH, Zisfein J, Sparano R. Single-dose oral phenytoin loading. Ann Emerg Med. 1987;16:407-412.
5. Dela Cruz FG, Kanter MZ, Fischer JH, et al. Efficacy of individualized phenytoin sodium loading doses administered by intravenous infusion. Clin Pharm. 1988;7:219-224.
6. Johnson J, Wrenn K. Inappropriate fosphenytoin use in the ED. Am J Emerg Med. 2001;19:293-294.
7. Touchette DR, Rhoney DH. Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department. Pharmacotherapy. 2000;20:908-916.
8. Meyer MC, Straughn AB. Biopharmaceutical factors in seizure control and drug toxicity. Am J Hosp Pharm. 1993;50(12 Suppl 5):S17-22.
9. Fierro LS, Savulich DH, Benezra DA. Safety of fosphenytoin sodium. Am J Health Syst Pharm. 1996;53:2707-2712.
10. Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage. JAMA 1983;249:762-765.
11. Bourgeois BF. Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? Neurology. 2000;55:S11-16.
12. Marchetti A, Magar R, Fischer J, et al. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments. Clin Ther. 1996;18:953-966.
13. Armstrong EP, Sauer KA, Downey MJ. Phenytoin and fosphenytoin: a model of cost and clinical outcomes. Pharmacotherapy. 1999;19:844-853.
14. Graves N. Pharmacoeconomic considerations in treatment options for acute seizures. J Child Neurol. 1998;13(Suppl 1):S27-29.
15. Swadron SP, Rudis MI, Aziman K, et al. A comparison of phenytoin-loading techniques in the emergency department. Acad Emerg Med. 2004;11:244-252.
16. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making. 1985;5:157-177.
17. Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decis Making. 1986;6:85-92.
18. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 1998;7:723-740.
19. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health. 2002;23:377-401.
20. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses: Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-1341.
21. Hielmgren J, Berggren F, Andersson F. Health economic guidelines: similarities, differences and some implications. Value Health. 2001;4:225-250.
22. Dsterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992;2:67-76.
23. Coplin WM, Rhoney DH, Rebuck JA, et al. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. Neurol Res. 2002;24:842-848.
24. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-1258.
25. Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies; practical applications and methodological shortcomings. Pharmacoeconomics. 1997;12(2 pt 1):121-129.
26. Evans C, Crawford B. Expert judgement in pharmacoeconomic studies: guidance and future use. Pharmacoeconomics. 2000;17:545-553.
27. Willan AR, D'Brien BJ, Leyva RA. Cost-effectiveness analysis when the WTA is greater than the WTP. Stat Med. 2001;20:3251-3259.